Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio is a promising clinical stage drug platform company with a positive outlook as its flagship candidate, buntanetap, has achieved statistical significance in early trials for Alzheimer's and other neurodegenerative diseases. With a strong FDA accepted trial protocol and enrollment completion for its phase 2 and 3 trials, the company has a potentially lucrative market ahead. Risks to the positive outlook include financing and pipeline risks, potential trial failures, and competition in the difficult-to-treat neurodegenerative market.

Bears say

Annovis Bio is currently collaborating on buntanetap, its flagship candidate currently in clinical trials for various neurodegenerative diseases, and has a 12-month DCF-based price target of $17. Despite potential launch in 2028E for early AD and a 25% probability of approval, it has not accounted for ex-US sales/royalties or other pipeline programs, and the 15% discount rate is reflective of a clinical-stage company's WACC.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.